H

Hassman Research Institute | Marlton, NJ

Research site

(Unclaimed)

Location

401 Route 73 N 30 Lake Center Executive Park, Marlton, New Jersey, United States of America

Site insights

Top conditions

Top treatments

KarXT

SEP-363856

BHV-7000

Ketamine

BI 1569912

Suzetrigine

SP-624

INDV-6001

IkT-148009

Roluperidone

Parent organization

This site is a part of Hassman Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 43 total trials

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized A...

Enrolling

Generalized Anxiety Disorder

Drug: MM120 (LSD D-Tartrate)

Other: Placebo

BHV-7000 Open-Label Extension Bipolar Mania Study

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.

Invitation-only

Bipolar Disorder

Drug: BHV-7000

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabet...

Enrolling

Diabetic Peripheral Neuropathic Pain

Drug: Suzetrigine

Drug: Placebo (matched to Pregabalin)

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated...

Invitation-only

Diabetic Peripheral Neuropathic Pain

Drug: Suzetrigine

INDV-6001 Multiple-Dose Pharmacokinetic Study

The current study will evaluate the pharmacokinetics, safety, and tolerability of INDV-6001 following multiple doses in participants with opioid use...

Enrolling

Moderate to Severe Opioid Use Disorder

Drug: Sublocade

Drug: INDV-6001